bepridil has been researched along with (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Azumi, H; Inoue, N; Kawashima, S; Nishi, H; Rikitake, Y; Takeshita, S; Yamashita, T; Yasuhara, M; Yokoyama, M | 1 |
1 other study(ies) available for bepridil and (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
| Article | Year |
|---|---|
Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits.
Topics: Animals; Antioxidants; Aorta; Arteriosclerosis; Bepridil; Biphenyl Compounds; Cells, Cultured; Cholesterol, Dietary; Copper; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluvastatin; Free Radical Scavengers; Free Radicals; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Indoles; Ions; Lipids; Lipoproteins, LDL; Male; Muscle, Smooth, Vascular; Picrates; Rabbits; Superoxides | 2001 |